4.5 Article

Temporal Trends and Factors Associated With Cardiac Rehabilitation Participation Among Medicare Beneficiaries With Heart Failure

期刊

JACC-HEART FAILURE
卷 9, 期 7, 页码 471-481

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.jchf.2021.02.006

关键词

cardiac rehabilitation; exercise training; heart failure; health care utilizatin; Medicare; predictors

资金

  1. Texas Health Resources Clinical Scholarship
  2. Gilead Sciences Research Scholar Program
  3. Applied Therapeutics
  4. National Institute of Aging [1R03AG067960-01]
  5. Abbott
  6. American Regent
  7. Amgen
  8. AstraZeneca
  9. Bayer
  10. Boehringer Ingelheim/Eli Lilly
  11. Boston Scientific
  12. Cytokinetics
  13. Fast BioMedical
  14. Gilead
  15. Innolife
  16. Medtronic
  17. Merck
  18. Novartis
  19. Relypsa
  20. Respicardia
  21. Roche
  22. Sanofi
  23. Vifor
  24. Windtree Therapeutics
  25. American Heart Association
  26. Intra-Cellular Therapies
  27. National Heart, Lung, and Blood Institute
  28. Patient-Centered Outcomes Research Institute

向作者/读者索取更多资源

This study aimed to assess the trends and factors associated with cardiac rehabilitation (CR) enrollment and participation among Medicare beneficiaries after the 2014 Medicare coverage expansion. The participation rates of CR among eligible patients with HF were low, with minimal increase since 2014. Factors such as younger age, male sex, nonblack race, previous cardiovascular procedures, and hospitalization at hospitals with CR facilities were associated with CR participation.
OBJECTIVES The purpose of this study was to assess temporal trends and factors associated with cardiac rehabilitation (CR) enrollment and participation among Medicare beneficiaries after the 2014 Medicare coverage expansion. BACKGROUND CR improves exercise capacity, quality of life, and clinical outcomes in heart failure (HF) with reduced ejection fraction (HFrEF). In 2014, Medicare coverage for CR was expanded to include chronic HFrEF. METHODS Among Medicare beneficiaries from quarter (Q) 1 2014 to Q2 2016, 11,696 patients from 14,258 hospitalizations with primary discharge diagnosis of HF were identified. Patients with HF with preserved ejection fraction were excluded. Quarterly CR participation rates among hospitalized HF patients within 6 months of discharge were identified through outpatient administrative claims. The predictors of CR participation were assessed with the use of a multivariable logistic regression model that included patient- and hospital-level characteristics. A secondary analysis to assess participation rates of CR after outpatient encounters for HF was performed. RESULTS Overall, only 611 (4.3%) and 349 (2.2%) eligible patients participated CR after primary hospitalization or outpatient visit for HF, respectively. There was a modest, statistically significant increase in CR participation after HF admissions (2.8% in Q1 2014; 5.0% in Q2 2016; p < 0.001) without significant increase after outpatient visits for HF (2.6% to 3.8%; p = 0.21). Younger age, male sex, nonblack race, previous cardiovascular procedures, and hospitalization at hospitals with available CR facilities were all independently associated with CR participation. CONCLUSIONS CR participation among eligible Medicare beneficiaries with HFrEF was low with minimal increase since 2014 Medicare coverage decision. Sex, race, and institution-dependent variables were independent predictors of CR participation. (C) 2021 by the American College of Cardiology Foundation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Endocrinology & Metabolism

Sex differences in the complications, care and clinical outcomes of patients with type 2 diabetes in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)

Jennifer B. Green, Peter Merrill, Yuliya Lokhnygina, Robert J. Mentz, Joakim Alfredsson, Rury R. Holman, EXSCEL Study Grp

Summary: This study aimed to examine sex differences in patients with type 2 diabetes (T2D) and compared the characteristics and outcomes between those treated with exenatide and placebo. The results showed that female patients had differences in age, duration of diabetes, and coronary artery disease compared to male patients, but had worse metabolic risk profiles and lower use of cardioprotective medications. Despite these factors, women had significantly lower rates of cardiovascular events.

DIABETES OBESITY & METABOLISM (2023)

Article Medicine, General & Internal

Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure The TRANSFORM-HF Randomized Clinical Trial

Robert J. Mentz, Kevin J. Anstrom, Eric L. Eisenstein, Shelly Sapp, Stephen J. Greene, Shelby Morgan, Jeffrey M. Testani, Amanda H. Harrington, Vandana Sachdev, Fassil Ketema, Dong-Yun Kim, Patrice Desvigne-Nickens, Bertram Pitt, Eric J. Velazquez

Summary: A randomized trial found that torsemide did not result in a significant difference in all-cause mortality compared with furosemide among patients hospitalized for heart failure. However, the interpretation of these findings is limited by loss to follow-up and participant crossover and nonadherence.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)

Editorial Material Cardiac & Cardiovascular Systems

JCF Heart Failure Year-In-Review 2022 ... The Best is Yet to Come! ...

Vanessa Blumer, Anuradha Lala, Robert J. Mentz

JOURNAL OF CARDIAC FAILURE (2023)

Review Cardiac & Cardiovascular Systems

Intravenous iron infusion in patients with heart failure: a systematic review and study-level meta-analysis

Husam M. M. Salah, Gianluigi Savarese, Giuseppe M. C. Rosano, Andrew P. P. Ambrosy, Robert J. J. Mentz, Marat Fudim

Summary: We conducted a meta-analysis of existing randomized controlled trials to evaluate the effect of intravenous iron infusion on cardiovascular outcomes in heart failure patients. The results showed that intravenous iron significantly reduced the risk of first hospitalization for heart failure and cardiovascular mortality, as well as the risk of total hospitalizations for heart failure. However, it had no significant impact on all-cause mortality or cardiovascular mortality alone.

ESC HEART FAILURE (2023)

Article Engineering, Biomedical

The Use of the Multisensor HeartLogic Algorithm for Heart Failure Remote Monitoring in Patients With Left Ventricular Assist Devices

Joseph B. Lerman, Derek D. Cyr, Karen Chiswell, Rachel S. Tobin, Marat Fudim, Sean D. Pokorney, Robert J. Mentz, Marc D. Samsky

ASAIO JOURNAL (2023)

Letter Medicine, General & Internal

Torsemide vs Furosemide After Discharge and All-Cause Mortality in Patients With Heart Failure Reply

Robert J. Mentz, Tracy A. DeWald, Eric J. Velazquez

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)

Letter Cardiac & Cardiovascular Systems

Efficacy and safety of torsemide versus furosemide in heart failure patients: A systematic review of randomized controlled trials

Huzaifa Ahmad Cheema, Saleha Azeem, Abdullah Ejaz, Faiza Khan, Anza Muhammad, Abia Shahid, Abdulqadir J. Nashwan, Muhammad Haisum Maqsood, Sourbha S. Dani, Robert J. Mentz, Marat Fudim, Gregg C. Fonarow

CLINICAL CARDIOLOGY (2023)

Review Cardiac & Cardiovascular Systems

High-Intensity Interval Training Versus Moderate Continuous Training in Patients With Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-analysis

Tariq Jamal Siddiqi, Ahmed Mustafa Rashid, Syed Sarmad Javaid, Ahmed Kamal Siddiqi, Muhammad Shariq Usman, Oliver Hervir, Daisuke Kamimura, Carl J. Lavie, Robert J. Mentz, Javed Butler, Michael E. Hall

Summary: High-intensity interval training (HIIT) significantly improved peak oxygen consumption (peak VO2) in patients with HFpEF compared to moderate continuous training (MCT). However, there were no significant changes in left atrial volume index (LAVI), respiratory exchange ratio (RER), and ventilatory efficiency (VE/CO2 slope) between HIIT and MCT in patients with HFpEF.

CURRENT PROBLEMS IN CARDIOLOGY (2023)

Article Cardiac & Cardiovascular Systems

Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis

Piotr Ponikowski, Robert J. Mentz, Adrian F. Hernandez, Javed Butler, Muhammad Shahzeb Khan, Dirk J. van Veldhuisen, Bernard Roubert, Nicole Blackman, Tim Friede, Ewa A. Jankowska, Stefan D. Anker

Summary: This meta-analysis of intravenous ferric carboxymaltose therapy for iron-deficient heart failure patients found a significantly reduced risk of hospitalizations for HF and cardiovascular causes, with no apparent effect on mortality.

EUROPEAN HEART JOURNAL (2023)

Editorial Material Cardiac & Cardiovascular Systems

Making Time for Diastole While Getting the Work Done

Anuradha Lala, Robert J. Mentz

JOURNAL OF CARDIAC FAILURE (2023)

Editorial Material Cardiac & Cardiovascular Systems

The Launch of the Association of Black Cardiologists (ABC)- JCF Mentorship Program in Academic Writing

Anuradha Lala, Anekwe Onwuanyi, Alanna A. Morris, Robert J. Mentz

JOURNAL OF CARDIAC FAILURE (2023)

Meeting Abstract Cardiac & Cardiovascular Systems

Patients With Type 2 Diabetes Are More Resistant To Diuresis And Have Worse Acute Heart Failure Outcomes: Findings From ASCEND-HF

Josephine Harrington, Stephen Greene, Jie-Lena Sun, Brooke Alhanti, Marat Fudim, Michael Felker, Javed Butler, Randall Starling, Christopher O'Connor, Adrian Hernandez, Robert Mentz

JOURNAL OF CARDIAC FAILURE (2023)

Meeting Abstract Cardiac & Cardiovascular Systems

Relationship Of Race With Outcomes Following A Novel Physical Rehabilitation Intervention In Older Patients Hospitalized For Heart Failure: Insights From REHAB-HF.

Vanessa Blumer, Olivia Gilbert, Robert Mentz, Haiying Chen, Alain Bertoni, David Whellan, Dalane Kitzman, Pamela Duncan, Gordon Reeves, Shelby D. Reed, Bharathi Upadhya, Christopher O'Connor, Amy Pastva

JOURNAL OF CARDIAC FAILURE (2023)

Meeting Abstract Cardiac & Cardiovascular Systems

Hand Grip Strength Predicts Mortality And Quality Of Life In Heart Failure: Insights From The Singapore Cohort Of Patients With Advanced Heart Failure

Kathy Z. Dai, Eric B. Laber, Robert J. Mentz, Huaxuan Chen, Chetna Malhotra

JOURNAL OF CARDIAC FAILURE (2023)

Meeting Abstract Cardiac & Cardiovascular Systems

PROTEOMIC MARKERS OF CARDIAC FIBROSIS AND ENDOTHELIAL FUNCTION ASSOCIATED WITH HEART FAILURE IN PATIENTS WITH DIABETES: AN EXSCEL BIOMARKER SUB-STUDY

Josephine Harrington, Maggie Nguyen, Jennifer Green, Naveed Sattar, Neha J. Pagidipati, Adrian F. Hernandez, Robert John Mentz, Harald Sourij, Rury R. Holman, Svati Shah

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2023)

暂无数据